Final Activity Report Summary - TLRS IN MS (Therapeutic targeting of the innate immune system in multiple sclerosis)
There were two main components of the study that ran in parallel: a Workpackage in the animal model of disease (WP1) and a Workpackage on human immune cells obtained from patients with MS and healthy control subjects (WP2). The goals of WP1 have been achieved by the identification of TLR agonists that are promising for their potential to suppress disease. The stimulation of some particular Toll-like receptors (TLRs, 'innate' immune receptors on which the research project focused) has been identified as promising, in particular the stimulation of TLR7 and TLR3.
At the end of the phase of the project funded by the Marie Curie International Reintegration Grant (month 24 of the project), the planned goals of WP2 have been achieved by obtaining initial data in human immune cells (mainly dendritic cells NK cells) which will be further tested in the remaining 12 months of the project (not funded by the IRG) in view of future clinical trials.
At the end of the phase of the project funded by the Marie Curie International Reintegration Grant (month 24 of the project), the planned goals of WP2 have been achieved by obtaining initial data in human immune cells (mainly dendritic cells NK cells) which will be further tested in the remaining 12 months of the project (not funded by the IRG) in view of future clinical trials.